产品管线
开创新一代疗法，为健康生活加码
产品管线
免疫
肿瘤/肿瘤免疫
-
项目(合作方)靶点适应症地区早期发现临床前IND一期二期三期BLA
-
查看更多
Porustobart（HBM4003）
CTLA-4
黑色素瘤, 肝细胞癌, 肾细胞癌及其他晚期实体瘤
黑色素瘤, 肝细胞癌, 神经内分泌肿瘤/癌及其他晚期实体瘤
晚期非小细胞肺癌及其他晚期实体瘤
全球
全球
全球
-
HBM7008
B7H4x4-1BB
实体瘤
全球
-
HBM7022
Claudin18.2xCD3
实体瘤
全球许可授权给阿斯利康
-
HBM1022
CCR8
实体瘤
全球
-
HBM1020
B7H7
实体瘤
全球
-
HBM1007
CD73
实体瘤
全球
-
查看更多
HBM9033
MSLN ADC
实体瘤
全球
-
查看更多
HBM9027
PD-L1xCD40
实体瘤
全球
-
查看更多
HBM1047
未披露
实体瘤
全球
-
查看更多
HBM7004
未披露
实体瘤
全球
-
和铂医药
-
合作方
-
注册临床试验
-
单一疗法
-
PD1 / 化疗
突破性认定疗法
科学论文和报告
-
An anti-CTLA-4 heavy chain-only antibody with enhanced T reg depletion shows excellent preclinical efficacy and safety profile
-
TNF-α inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China
-
Therapeutic Response and Possible Biomarkers in Acute Attacks of Neuromyelitis Optica Spectrum Disorders: A Prospective Observational Study
-
Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers
-
SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model
-
A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies
-
Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes
-
A human monoclonal antibody blocking SARS-CoV-2 infection
-
Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein
-
Cell Engager Summit Exclusive Speaker Interview
-
Preclinical evaluation of HBM7022, an HBICE™ 2+1 CLDN18.2 x CD3 bispecific antibody, for gastric cancer
-
Development of fully human T-cell engaging bispecific antibodies targeting B7H4
-
Discovery of potent and functional human antibodies against a new B7-family member, B7H7, for cancer immunotherapy
-
HCAb Based Bispecific Immune Cell Engager (HBICE) Platform Enables Fast And Convenient Generation of the Next Generation Bispecific Antibodies with High Potency, Promising Safety Profiles and Excellent Developability
-
HBM1022, a Novel Anti-CCR8 Antibody, Depletes Tumor-infiltrating Regulatory T cells via Enhanced ADCC Activity, Mediates Potent Anti-Tumor Activity
-
Novel Monoclonal Antibodies (mAbs) Targeting Human CCR8 Provide Potential Candidates for Next Generation Cancer Immunotherapy
-
HBM1007 – A Highly Potent Anti-CD73 mAb Candidate For Mono And Combination IO Therapy
-
BCMA x CD3 Bispecific Antibody – A novel HBICE™-based Molecule with Efficient Tumor Killing and Minimal Cytokine Release
-
A New Generation of Fully Human anti-CTLA-4 Heavy Chain Only Antibody
